Celldex (CLDX) Announces up to $175M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celldex (CLDX) Prices Upsized 5.95M Share Offering at $42/sh
July 14, 2021 5:04 AM EDTCelldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 892,857 shares of common stock at the public offering price, less underwriting discounts and commissions.
Jefferies, SVB Leerink, Guggenheim Securities and Cantor are acting as the joint book-running managers for the offering. LifeSci Capital LLC and H.C. Wainwright & Co. are acting as co-lead... More
Celldex Therapeutics (CLDX) PT Raised to $61 at Cantor Fitzgerald
July 12, 2021 1:22 PM EDTCantor Fitzgerald analyst Kristen Kluska raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $61.00 (from $35.00) while maintaining a Overweight rating.
... MoreCelldex Therapeutics (CLDX) Gains on CDX-0159 Update, Which Has Drug 'In the Driver's Seat'
July 12, 2021 10:18 AM EDTCelldex Therapeutics (NASDAQ: CLDX) shares are ramping 30% in early trading Monday following updated data from the companys ongoing Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria.
The update highlights several key metrics:
All 19/19 (100%) patients experienced a clinical response as assessed by provocation threshold testing; 18/19 (95%) experienced a complete response and 1/19 (5%) experienced a partial response.Rapid onset of responses after... MorePre-Open Stock Movers 07/12: (STFC) (CLDX) (SPI) Higher; (TBLT) (DIDI) (RKT) Lower (more...)
July 12, 2021 9:28 AM EDTPre-Open Stock Movers
State Auto Financial Corporation (NASDAQ: STFC) 189% HIGHER; Liberty Mutual Holding Company Inc., State Automobile Mutual Insurance Company, and State Auto Financial Corporation (NASDAQ: STFC) announced today that they have signed a definitive agreement pursuant to which Liberty Mutual would acquire State Auto Group, a super-regional insurance holding company headquartered in Columbus, Ohio. Under the terms of the agreement, State Auto mutual members will become mutual members of Liberty Mutual and Liberty Mutual will acquire all of the publicly held... More
Celldex Therapeutics (CLDX) PT Raised to $50 at H.C. Wainwright
July 12, 2021 6:21 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $50.00 (from $36.00) while maintaining a Buy rating following updated Phase 1b data from the ongoing Phase 1b study of CDX-0159.
The analyst commented, "Celldex reported updated Phase 1b data from the ongoing Phase 1b study of... More
